Studies have found that in a mouse model of pancreatic cancer, the addition of IL-35-blocking antibodies to STING agonists effectively improved the effects of tumor-infiltrating NK cells, thereby achieving antitumor effects.215 B cells can also differentiate into plasma cells in TLSs and LMAs, and patients with many B cells and TLSs and a high plasma cell signature had a longer OS and better prognosis when treated with ICIs.214,216–218. The gene discussed is STING1; the disease is neoplasm.